Yilihua: ETH is expected to reach $7,000 in this cycle, with multiple positive factors set to trigger a new bull market
BlockBeats News, November 9, Liquid Capital (formerly LD Capital) founder Yi Lihua once again called for Ethereum: "In this round, ETH is targeting $7,000. Nothing is more important than the midterm elections, and nothing is more beneficial to the midterms than distributing money. Looking back at the 2020 pandemic bull market, the core driving force of the market was also the distribution of money to everyone. Recent research and investment data all point to positive expectations, and with the accumulation of short positions in the market, everything is ready for a new bull market to begin. All that is needed is patience and to avoid touching contracts as much as possible, since spot volatility is already significant enough. It has only been a few months since the ETH rally started in April. Buffett once said that no one wants to get rich slowly, because humans have an innate urge for quick success, and we need to work hard to overcome these human weaknesses."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
